OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Dahiya on the Pathobiology of Second Primary Cancers After CAR T-Cell Therapy

January 31st 2025

Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.

Dr Ostwal on T-DM1 in Pretreated HER2+ Advanced Biliary Tract Cancer

January 30th 2025

Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.

Dr Spira Details Future Directions for Amivantamab in NSCLC

January 30th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

Dr Duvall on Unanswered Questions Regarding the Optimal Role for Blinatumomab in B-ALL

January 30th 2025

Adam DuVall, MD, MPH, discusses remaining questions regarding the optimal use of blinatumomab in frontline B-ALL.

Dr Davila on Efforts to Overcome CD19-Directed CAR T-Cell Therapy Resistance in LBCL

January 30th 2025

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

Dr Popat on the Efficacy and Safety Profiles of Zongertinib in HER2-Mutated NSCLC

January 30th 2025

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Dr Bardia on the FDA Approval of T-DXd for HER2-Low/-Ultralow Metastatic Breast Cancer

January 30th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of T-DXd for patients with pretreated HER2-low and -ultralow metastatic breast cancer.

Dr Foote on the Ongoing Debate Over Upfront EGFR Inhibitor Use in CRC

January 30th 2025

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

Dr Kaddoura on Challenges Integrating Whole Genome Sequencing Into Clinical Practice in Myeloma

January 30th 2025

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Dr André on Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC

January 29th 2025

Thierry André, MD, discusses the efficacy of nivolumab plus ipilimumab vs nivolumab monotherapy in MSI-H/dMMR mCRC.

Dr Dreyling on the Potential for Chemotherapy-Free Treatments in MCL

January 29th 2025

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

Dr Choueiri on the Significance of Targeting HIF-2α With NKT2152 in ccRCC

January 29th 2025

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers

January 29th 2025

Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.

Dr Siegel on the Current and Future Role of Mezigdomide in Multiple Myeloma

January 29th 2025

David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.

Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs

January 29th 2025

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Dr DeAngelo on the FDA Approval of Obe-Cel in R/R B-Cell Precursor ALL

January 29th 2025

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Dr Ip on Real-World Data Informing CAR T-Cell Therapy Selection in LBCL

January 29th 2025

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

January 28th 2025

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Dr Shaukat on the PREEMPT CRC Blood-Based Assay for Average-Risk CRC

January 28th 2025

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Dr Shah on the Effect of IVIG on Infection Risk in R/R Multiple Myeloma

January 28th 2025

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.